Loading...
•
Dec 31, 2019
Zimmer Biomet Q4 2019 Earnings Report
Zimmer Biomet reported an increase in fourth quarter net sales and provided full-year 2020 guidance.
Key Takeaways
Zimmer Biomet announced fourth quarter net sales of $2.126 billion, a 2.6% increase over the prior year period, and diluted EPS of $1.54. Adjusted diluted EPS were $2.30, a 5.5% increase over the prior year period. The company provided full-year 2020 revenue growth guidance of 2.5% to 3.5%.
Fourth quarter net sales increased 2.6%, 3.2% on a constant currency basis.
Fourth quarter diluted EPS were $1.54; adjusted diluted EPS were $2.30.
Key drivers in the fourth quarter included solid performance from the Americas and Asia Pacific, with continued strong results across our global Knee and Hip businesses.
ROSA® Knee System sales accelerated from the third quarter of 2019.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company is providing the following full-year 2020 financial guidance: Company expects 2.5% to 3.5% revenue growth on a reported and constant currency basis.
Positive Outlook
- Company expects 2.5% to 3.5% revenue growth on a reported and constant currency basis
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...